Europe
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.
To date, all the major clinical trials of vaccines against COVID-19 have been in adults.
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually to commercialization.
In August, Nestlé gobbled up Aimmune in a $2.6 billion deal, and now the food allergy-focused company will serve as the point pharmaceutical business for Nestlé Health Science.
In a Phase III study, the biologic (Dupixent) met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
PRESS RELEASES